| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
95,370,000 |
| Market
Cap: |
1.63(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
423,909 |
| 52
Week Range: |
$17.23 - $158 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1293 |
| Guru Rank Value : -8 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
37,038 |
180,795 |
| Total Buy Value |
$0 |
$0 |
$4,955,728 |
$18,250,796 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
2,491 |
20,612 |
63,343 |
| Total Sell Value |
$0 |
$248,203 |
$2,586,523 |
$7,686,364 |
| Total People Sold |
0 |
1 |
4 |
8 |
| Total Sell Transactions |
0 |
1 |
4 |
12 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barry Richard |
|
– • – |
2025-05-16 |
4 |
OE |
$32.63 |
$402,981 |
D/D |
12,350 |
2,966,667 |
|
- |
|
| Barry Richard |
|
– • – |
2025-05-13 |
4 |
OE |
$13.71 |
$389,359 |
D/D |
20,246 |
2,954,317 |
|
- |
|
| Nicaise Claude |
|
– • – |
2025-03-12 |
4 |
S |
$99.64 |
$248,203 |
D/D |
(2,491) |
27,812 |
|
83% |
|
| Nicaise Claude |
|
– • – |
2025-03-12 |
4 |
OE |
$25.18 |
$245,404 |
D/D |
9,746 |
30,303 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,276 |
62,612 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2025-03-10 |
4 |
D |
$100.13 |
$394,612 |
D/D |
(3,941) |
54,336 |
|
- |
|
| Arif Bilal |
Chief Tech Ops Officer |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,276 |
32,500 |
|
- |
|
| Arif Bilal |
Chief Tech Ops Officer |
• – – |
2025-03-10 |
4 |
D |
$100.13 |
$52,368 |
D/D |
(523) |
24,224 |
|
- |
|
| Chambers Michael Andrew |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
10,660 |
|
- |
|
| Connelly Deirdre P |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
5,225 |
|
- |
|
| Behrens M Kathleen |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
193,476 |
|
- |
|
| Barry Richard |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
2,934,071 |
|
- |
|
| Nicaise Claude |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
20,557 |
|
- |
|
| Boor Kathryn Jean |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
8,263 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
25,223 |
|
- |
|
| Mayo Stephen |
|
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,383 |
9,004 |
|
- |
|
| Murray Dallan |
Chief Customer Officer |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,276 |
38,202 |
|
- |
|
| Murray Dallan |
Chief Customer Officer |
• – – |
2025-03-10 |
4 |
D |
$100.13 |
$373,785 |
D/D |
(3,733) |
29,926 |
|
- |
|
| Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,276 |
84,631 |
|
- |
|
| Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2025-03-10 |
4 |
D |
$100.13 |
$346,750 |
D/D |
(3,463) |
76,355 |
|
- |
|
| Rothfuss Cristin |
EVP, General Counsel |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,276 |
21,110 |
|
- |
|
| Rothfuss Cristin |
EVP, General Counsel |
• – – |
2025-03-10 |
4 |
D |
$100.13 |
$49,164 |
D/D |
(491) |
12,834 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2025-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
58,277 |
|
- |
|
| Murray Dallan |
Chief Customer Officer |
• – – |
2025-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
33,659 |
|
- |
|
| Rodino-Klapac Louise |
Head of R&D, CSO |
• – – |
2025-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
79,818 |
|
- |
|
408 Records found
|
|
Page 1 of 17 |
|
|
0.12 (0.7%) 
